With the introduction of mRNA vaccines in the 2010s – vaccines that use messenger RNA molecules in cells to train the body to fight dangerous invaders – doctors found a promising new tool in the fight against the disease. Now some say they’ve gotten a step closer to stopping cancer in its tracks.

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab in advanced melanoma at the 2026 AACR Annual Meeting. The company reports encouraging response rates and a favorable safety profile for the investigational combination in early stage testing.

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC

Indian American physician-scientist Dr. Vinod Balachandran says mRNA vaccines may reduce risk of disease coming back after surgery.

Dr. Elias Sayour says the mRNA vaccine is helping shed new light on cancer treatments. “There have been patients that have been in remission for years as a result of receiving these treatments,” the University of Florida professor told “Jesse Weber Live” on Tuesday.

The FDA has assigned mRNA-1010 a PDUFA target date of 5 August 2026. If approved, mRNA-1010 will be the first seasonal influenza mRNA vaccine on the market.

WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and treatments against a long list of diseases, including ...

That is the grim prognosis facing patients with pancreatic cancer. Researchers have developed a personalized messenger RNA vaccine that could change this reality. At the end of a clinical trial, seven of the eight patients who developed an immune response to the treatment are still alive and in good health,

The treatment staved off cancer for seven of eight patients with a condition where the odds are rarely that good.